$1.53▲ 0.28 (22.40%)
Real-time prices · US MarketsClean balance sheet with low leverage (0.4× debt-to-equity).
low return on equity (-52%).
Quality
1.6
Health
9.7
Growth
4.7
Valuation
6.5
Sentiment
5.2
Analyst Target
$5.19
▲ +239.1% from current
Price Chart
Latest News
- Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting
- Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting
Fundamentals
Trailing P/E
—
price-to-earnings
Forward P/E
-1.5×
next 12 months est.
Market Cap
$178M
market capitalization
Div Yield
—
dividend yield
Profit Margin
0.0%
net profit margin
Gross Margin
0.0%
revenue minus COGS
ROE
-51.8%
return on equity
Beta
2.24
vs S&P 500
Price / Book
—
P/B ratio
52-Week Range
$1 — $2
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
Is FATE a good stock to buy right now?
Fate Therapeutics, Inc.'s Q·Score is 5.4/10 (Bearish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.4× debt-to-equity). Key area to monitor: low return on equity (-52%). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for FATE?
The consensus price target for FATE is $5.19, based on ratings from 8 Wall Street analysts. This is 239.1% above the current price of $1.53. Price targets are forward-looking estimates and not guarantees of future performance.
Is FATE overvalued or undervalued?
Fate Therapeutics, Inc. (FATE) scores in line with sector averages on valuation metrics. The consensus analyst price target of $5.19 is 239% above the current price.
When does Fate Therapeutics, Inc. report its next earnings?
Fate Therapeutics, Inc. is scheduled to report earnings in 9 days, on May 12, 2026.
What is Fate Therapeutics, Inc.'s profit margin?
Fate Therapeutics, Inc. has a net profit margin of 0.0%, indicating the company is currently operating at a net loss. Its gross margin stands at 0.0%, reflecting a more cost-intensive business model.
Is Fate Therapeutics, Inc.'s revenue growing?
Fate Therapeutics, Inc. is reporting revenue declining 26.4% year-over-year.
How much debt does Fate Therapeutics, Inc. have?
Fate Therapeutics, Inc. has a debt-to-equity ratio of 0.38×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 5.79×, indicating comfortable short-term liquidity.